News
CDT
0.8401
-35.87%
-0.4699
CDT Equity Receives Potential $2 Per Share Acquisition Offer
TipRanks · 12h ago
Weekly Report: what happened at CDT last week (1102-1106)?
Weekly Report · 16h ago
Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Benzinga · 17h ago
Corvus Capital Proposes To Acquire CDT Equity At $2 Per Share
Benzinga · 3d ago
CDT Equity Inc trading halted, news pending
TipRanks · 4d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 5d ago
CDT Equity Announces 1-for-20 Reverse Stock Split
TipRanks · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/02 21:05
Weekly Report: what happened at CDT last week (1026-1030)?
Weekly Report · 11/02 10:03
Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/29 08:55
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 10/28 21:05
Why Ultra Clean Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/28 08:48
CDT Equity expands into animal health through Manoira deal
TipRanks · 10/27 12:53
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/26 17:05
Weekly Report: what happened at CDT last week (1019-1023)?
Weekly Report · 10/26 10:02
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 10/21 21:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/20 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/19 17:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/19 12:05
Weekly Report: what happened at CDT last week (1012-1016)?
Weekly Report · 10/19 10:02
More
Webull provides a variety of real-time CDT stock news. You can receive the latest news about CDT Equity through multiple platforms. This information may help you make smarter investment decisions.
About CDT
CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.